These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 21116000

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R, Lacouture M, Wu S.
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.
    Yardley DA.
    Clin Breast Cancer; 2014 Oct; 14(5):297-308. PubMed ID: 25065566
    [Abstract] [Full Text] [Related]

  • 26. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M, Elaidi R, Brizard M, Fouque J, Takouchop C, Sabatier B, Oudard S, Medioni J.
    BMC Cancer; 2017 Jan 06; 17(1):27. PubMed ID: 28061764
    [Abstract] [Full Text] [Related]

  • 27. [Use of mTOR-inhibitors in solid tumors].
    Seidel C, Grünwald V.
    Med Monatsschr Pharm; 2011 Apr 06; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL.
    BMC Cancer; 2010 Jul 14; 10():368. PubMed ID: 20630061
    [Abstract] [Full Text] [Related]

  • 29. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
    Ortolani S, Ciccarese C, Cingarlini S, Tortora G, Massari F.
    Future Oncol; 2015 Jul 14; 11(12):1809-28. PubMed ID: 26075448
    [Abstract] [Full Text] [Related]

  • 30. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R, Boni JP, Ravaud A.
    Cancer Treat Rev; 2013 Nov 14; 39(7):784-92. PubMed ID: 23375248
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
    Inglis DJ, Lavranos TC, Beaumont DM, Leske AF, Brown CK, Hall AJ, Kremmidiotis G.
    Cancer Biol Ther; 2014 Nov 14; 15(11):1552-60. PubMed ID: 25482941
    [Abstract] [Full Text] [Related]

  • 33. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.
    Curr Med Res Opin; 2014 Oct 14; 30(10):2041-50. PubMed ID: 24983741
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ, Hsu A.
    Clin J Oncol Nurs; 2008 Aug 14; 12(4):639-46. PubMed ID: 18676330
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L, Zhou Y, Ye X, Zhao Q.
    Tumour Biol; 2015 Feb 14; 36(2):643-54. PubMed ID: 25281033
    [Abstract] [Full Text] [Related]

  • 38. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX, Huang YJ, Yao Y, Shen Z, Min DL.
    PLoS One; 2013 Feb 14; 8(6):e65166. PubMed ID: 23785409
    [Abstract] [Full Text] [Related]

  • 39. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.
    Int J Clin Oncol; 2015 Aug 14; 20(4):790-5. PubMed ID: 25342378
    [Abstract] [Full Text] [Related]

  • 40. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
    Smolewski P.
    Anticancer Drugs; 2006 Jun 14; 17(5):487-94. PubMed ID: 16702804
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.